PharmiNews

The Directory of Pharma Companies and News

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
Category: Pharmaco
Category: Pharmaco
Keywords: cancer,

Boehringer Ingelheim News

DateNews
2015-12-22Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
2015-12-21Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
2015-12-18Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to ge...
2015-12-15Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
2015-12-14Initiation of first multinational study to evaluate safety of OFEV® (nintedanib) with add-on of pirfenidone in patients ...
2015-12-08New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis
2015-12-02Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cance...
2015-11-30Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised ...
2015-11-26Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
2015-11-17Time is of the essence for millions living with ‘neglected’ lung disease
2015-11-16Boehringer Ingelheim named one of the most innovative companies worldwide
2015-11-13New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
2015-11-11Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the d...
2015-11-10Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Car...
2015-11-10Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
2015-11-10Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab
2015-11-09New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
2015-11-06Change in Board of Managing Directors to ensure continuity and focus on the future
2015-11-06EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015
2015-11-03Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound
2015-10-28CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
2015-10-28Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab
2015-10-19FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
2015-10-15Boehringer Ingelheim Animal Health presents its first live web congress on Bovine Viral Diarrhoea
2015-10-12Boehringer Ingelheim and Philogen collaborate to investigate novel treatment approaches for Acute Myeloid Leukemia
2015-10-09Boehringer Ingelheim Animal Health announces winners of the 2015 European PRRS Research Award
2015-10-08Delayed IPF diagnosis negatively impacts patients by delaying treatment according to global survey of pulmonologists1
2015-10-08Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II ...
2015-09-29New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with I...
2015-09-28COPD: New data support role of Spiolto® Respimat® as 1st-line maintenance therapy and show superiority over LABA/ICS
2015-09-27VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compar...
2015-09-25CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)
2015-09-25Extending overall survival is less important than quality of life and disease stability for the majority of physicians t...
2015-09-25New data show only 40% of physicians treating advanced lung cancer considered extension of life to be the most important...
2015-09-22Boehringer Ingelheim Animal Health launches two new swine vaccines in Europe
2015-09-21ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments
2015-09-21Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic r...
2015-09-17Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascula...
2015-09-16Asthma: U.S. FDA approves new indication for SPIRIVA® Respimat®
2015-09-15EASD: Additional Evidence Showed ABASAGLAR® (insulin glargine) Provided Safety and Efficacy Similar to Lantus®
2015-09-15Type 2 diabetes: International survey shows quality of patient-physician conversation at diagnosis linked to better pati...
2015-09-08New data show that more than 50% of patients and carers struggled to cope with challenges of living with lung cancer
2015-09-07European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX® during pregnancy and lactation in sows
2015-09-01Boehringer Ingelheim licenses Vectron Biosolutions’ expression technology platform
2015-08-29ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelh...
2015-08-28Expansion of the Boehringer Ingelheim Board of Managing Directors / Andreas Neumann responsible for Human Resources
2015-08-25FDA and EMA accept regulatory applications for Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) for treatment of a...
2015-08-20Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
2015-08-19CHMP recommends label update for Giotrif® with addition of data demonstrating overall survival benefit for patients with...
2015-08-17New data show Spiolto® Respimat® provides meaningful quality of life improvements in COPD
2015-08-12Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity
2015-08-04Boehringer Ingelheim experiences slight growth in local currency terms in the first half of 2015
2015-07-28Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR...
2015-07-24MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke
2015-07-15Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for...
2015-07-06Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) comp...
2015-07-02New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries
2015-07-01Boehringer Ingelheim Animal Health: 2015 European PRRS Research Award open for submissions until July 31st
2015-06-22Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study
2015-06-16New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers
2015-06-08Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care
2015-06-08Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA
2015-06-03NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung...
2015-05-31ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients w...
2015-05-28Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union
2015-05-28Boehringer Ingelheim and researchers at The University of Michigan collaborate to study mechanisms of diabetic nephropat...
2015-05-27Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s®...
2015-05-26FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
2015-05-21Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Ca...
2015-05-20Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT 2011 evidence based guidelines for treatment of idiopat...
2015-05-20New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy1,2,3
2015-05-18New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks an...
2015-05-18Data Comparison shows onset of action of oral hyoscine butylbromide already as early as 15 minutes
2015-05-18Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate
2015-05-14Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of af...
2015-05-13First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation
2015-04-222014: Boehringer Ingelheim positioned for future growth with product launches
2015-04-17New international survey of lung cancer oncologists highlights underutilization of personalized treatments
2015-04-13Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders
2015-03-30Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union
2015-03-20Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis ...
2015-03-03Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate...
2015-02-24Boehringer Ingelheim Animal Health continues support of independent PCV2 research
2015-01-27New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD
2015-01-1535 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia
2015-01-14Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
2015-01-13Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeut...
2015-01-12The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lun...
2014-12-15First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined s...
2014-11-27Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemot...
1970-01-01\u003cspan style=\"line-height: 1.4;\"\u003eMundipharma announced an agreement with Orexo granting Mundipharma’s network... (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.